213 related articles for article (PubMed ID: 32485707)
1. Associations between Proton Pump Inhibitor and Histamine-2 Receptor Antagonist and Bone Mineral Density among Kidney Transplant Recipients.
Lyu B; Hansen KE; Jorgenson MR; Astor BC
Am J Nephrol; 2020; 51(6):433-441. PubMed ID: 32485707
[TBL] [Abstract][Full Text] [Related]
2. Proton Pump Inhibitors, But Not H2-receptor Antagonists, Are Associated With Incident Fractures Among Kidney Transplant Recipients.
Lyu B; Jorgenson MR; Hansen KE; Djamali A; Astor BC
Transplantation; 2020 Dec; 104(12):2609-2615. PubMed ID: 32058466
[TBL] [Abstract][Full Text] [Related]
3. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.
Targownik LE; Lix LM; Leung S; Leslie WD
Gastroenterology; 2010 Mar; 138(3):896-904. PubMed ID: 19931262
[TBL] [Abstract][Full Text] [Related]
4. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitors use and change in bone mineral density.
Arj A; Razavi Zade M; Yavari M; Akbari H; Zamani B; Asemi Z
Int J Rheum Dis; 2016 Sep; 19(9):864-8. PubMed ID: 27242025
[TBL] [Abstract][Full Text] [Related]
6. Acid-suppressive medications and risk of bone loss and fracture in older adults.
Yu EW; Blackwell T; Ensrud KE; Hillier TA; Lane NE; Orwoll E; Bauer DC
Calcif Tissue Int; 2008 Oct; 83(4):251-9. PubMed ID: 18813868
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.
Solomon DH; Diem SJ; Ruppert K; Lian YJ; Liu CC; Wohlfart A; Greendale GA; Finkelstein JS
J Bone Miner Res; 2015 Feb; 30(2):232-9. PubMed ID: 25156141
[TBL] [Abstract][Full Text] [Related]
8. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).
Targownik LE; Leslie WD; Davison KS; Goltzman D; Jamal SA; Kreiger N; Josse RG; Kaiser SM; Kovacs CS; Prior JC; Zhou W;
Am J Gastroenterol; 2012 Sep; 107(9):1361-9. PubMed ID: 22777336
[TBL] [Abstract][Full Text] [Related]
9. Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.
Vangala C; Niu J; Lenihan CR; Mitch WE; Navaneethan SD; Winkelmayer WC
Clin J Am Soc Nephrol; 2018 Oct; 13(10):1534-1541. PubMed ID: 30262672
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.
Yu EW; Bauer SR; Bain PA; Bauer DC
Am J Med; 2011 Jun; 124(6):519-26. PubMed ID: 21605729
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
12. Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamine-2 Receptor Antagonists.
Patel KS; Stephany BR; Barnes JF; Bauer SR; Spinner ML
Pharmacotherapy; 2017 Dec; 37(12):1507-1515. PubMed ID: 28976570
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
Gray SL; LaCroix AZ; Larson J; Robbins J; Cauley JA; Manson JE; Chen Z
Arch Intern Med; 2010 May; 170(9):765-71. PubMed ID: 20458083
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes of Acid Suppressive Therapy Use in Hematology/Oncology Patients at an Academic Medical Center.
McCaleb RV; Gandhi AS; Clark SM; Clemmons AB
Ann Pharmacother; 2016 Jul; 50(7):541-7. PubMed ID: 27091869
[TBL] [Abstract][Full Text] [Related]
15. Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
Van De Sijpe G; Beuselinck B; Van Nieuwenhuyse T; Poncelet R; Bechter O; Albersen M; Roussel E; Baldewijns M; Tack J; Spriet I
Eur J Clin Pharmacol; 2020 Sep; 76(9):1273-1280. PubMed ID: 32474662
[TBL] [Abstract][Full Text] [Related]
16. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
[TBL] [Abstract][Full Text] [Related]
17. Choice of Acid Suppressant Therapy and Long-Term Graft Outcomes After Kidney Transplantation.
January SE; Progar K; Nesselhauf NM; Hagopian JC; Malone AF
Pharmacotherapy; 2020 Nov; 40(11):1082-1088. PubMed ID: 33037663
[TBL] [Abstract][Full Text] [Related]
18. Long-term continuous use of proton-pump inhibitors is associated with renal function decline in patients without acute kidney injury.
Hatakeyama Y; Horino T; Matsumoto T; Terada Y; Okuhara Y
Clin Exp Nephrol; 2021 Oct; 25(10):1087-1092. PubMed ID: 34089392
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
20. Proton Pump Inhibitor Use and Risk of Hip Fracture in Kidney Transplant Recipients.
Lenihan CR; Sukumaran Nair S; Vangala C; Ramanathan V; Montez-Rath ME; Winkelmayer WC
Am J Kidney Dis; 2017 May; 69(5):595-601. PubMed ID: 27866965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
